broad institute
-
Scholars call for global moratorium on human gene editing following ‘CRISPR babies’ scandal
The 18 signatories emphasized that the moratorium wouldn’t constitute a ban or include gene editing for research or treatment of diseases, but called on nations to develop a framework to govern the practice.
-
Hospitals, Artificial Intelligence
IBM Watson Health invests $50M in research collaborations, teams up with Broad Institute to predict risk of cardiovascular disease
These two announcements come after Deborah DiSanzo left her role as IBM Watson Health general manager last year.
-
Do you advise self-insured employers? You Can Help Us!
Take part in this survey and share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health and navigation.
-
CRISPR Therapeutics, ViaCyte partner on diabetes therapies
In a deal worth up to $25 million for ViaCyte, the companies will work together to create allogeneic stem cell therapies to treat the disease.
-
Broad Institute partners with Amazon, Google, IBM to bring genome analysis software to the cloud
The Broad Institute plans to develop and roll out GATK4, the next generation version of Genome Analysis Toolkit. The new service will include cancer, structural variation, copy number variation and related functionality.
-
Broad Institute licenses CRISPR/Cas9 tech to Transposagen
Transposagen, a Kentucky biotech that develops research tools and animal models for drug discovery, will add CRISPR technology to its existing suite of gene editing tools.
-
Former Biogen R&D head launches exosome-based biotech with $80M
Former Biogen R&D chief Doug Williams is launching a biotech startup called Codiak BioSciences with $80 million. It is developing exosomes as a new diagnostic and therapeutic tool, beginning with pancreatic cancer.